Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 4Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Upper Tract Urothelial Carcinomas 1Lymphedema 1Breast Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × Drug Evaluation × Clear all
NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated
39 enrolled 31 charts
Genitourinary

Upper Tract Urothelial Carcinomas

NCT02538471 2019-12-09

LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer

Weill Medical College of Cornell University

Phase 2 Terminated
3 enrolled 11 charts
Breast

Breast Neoplasms

NCT01893879 2017-05-18

PCTTPL

Stanford University

Phase NA Terminated
14 enrolled 5 charts

Lymphedema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡